ArticleCurrent research in physiology2025
Exploration of neural mechanisms underlying antidepressant-like property of
Article in Current research in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: The chemical profile of EOZC obtained by GC-MS. The mice received EOZC (10, 20, and 40 mg/kg) 1 h before the FST intraperitoneally. Moreover, naloxone (non-selective antagonist for opioid receptor subtypes, 1 mg/kg), prazosin (α Results: The GC-MS evaluation demonstrated that predominant components of EOZC comprised carvacrol (65.22 %), thymol (19.51 %), p-cymene (4.86 %), γ-terpinene (4.63 %) and E-Caryophyllene (1.07 %). EOZC exhibited a significant dose-dependent effect that resulted in a marked decrease in the duration of immobility time (P < 0.05). The antidepressant-like action of EOZC was reversed by prazosin, yohimbine, WAY100635, ondansetron, haloperidol, SCH23390 and sulpiride. However, this effect remained unaffected by naloxone, propranolol and flumazenil. Conclusion: These findings indicate that EOZC elicits antidepressant-like response, which relies on its interaction with noradrenergic, serotonergic and dopaminergic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.